RSV? NO, SIREE!!!

I WANT TO KNOW… IF IT HAPPENED BEFORE, WHY IT CAN’T HAPPEN AGAIN

(My words in red.)

http://www.ncbi.nlm.nih.gov/pubmed/11587806Immunopathogenesis of vaccine-enhanced RSV disease.Openshaw PJ, Culley FJ, Olszewska W.Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine at St. Mary's, Norfolk Place, W2 1PG, London, UK. p.openshaw@ic.ac.uk Inducing a strong immune response is an essential aim of vaccination. Although immune responses to virus infections are usually protective, they can also be harmful. The best-documented examples of an immune response increasing disease severity are with dengue, measles and respiratory syncytial virus infections. In the 1960s, administration of formalin-inactivated, tissue culture grown RSV (FI-RSV) was found to induce strong ELISA binding but poor virus-neutralising antibody. Infants given this 'lot 100' vaccine appeared to exhibit an increased rate of RSV infection during subsequent natural RSV outbreaks. Although it has not been possible to exactly delineate the cause of disease enhancement in man, animal models strongly suggest that it was due to strong (and perhaps unbalanced) T cell priming rather than infection-enhancing or sensitising antibody. In animal models, enhanced disease can result from over-exuberant T cell priming which recruits an abundant inflammatory infiltrate in the lung (the nature of which depends on the patterns of cytokines and chemokines produced). Formalin-treated RSV vaccination has been linked specifically to the induction of Th2 cells, which make IL-4 and IL-5 and induce a strong pulmonary eosinophilic response. The vaccine dosing regime and the interval between vaccination and challenge can be critical to the induction of protection or pathology. Defining the correlates of protection and disease enhancement in man is critical to the rational development of effective and protective vaccines against RSV.

Here is what the village idiots have to say on the subject:

Vaccine -- The ultimate prevention step would be vaccination. Researchers have been hard at work trying to develop a safe and effective vaccine for RSV for more than 25 years. After a lot of setbacks, there now seems to be a lead in developing this vaccine. Early studies have proved promising, and hopefully, this vaccination will be available within the 5-10 years. Read More http://parenting.ivillage.com/baby/bhealth/0,,3qfx,00.html#ixzz0jS9oQfbx http://parenting.ivillage.com/baby/bhealth/0,,3qfx,00.html

RECAP:

“The ultimate prevention step would be vaccination. Researchers have been hard at work trying to develop a safe and effective vaccine for RSV for more than 25 years. After a lot of setbacks, there now seems to be a lead in developing this vaccine. Early studies have proved promising, and hopefully, this vaccination will be available within the 5-10 years."

Do you really want them to EXPERIMENT on your baby?

Have a gander at this: (Notice date)

NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results ... 12 Mar 2010 ... To date, there are no approved vaccines available for RSV. ... development of the RSV vaccine candidate. Anticipated events in 2010: ... telephone at 1 (866) 804-3550 (U.S. or Canada) or 1 (703) 639-1330 (International). ...www.your-story.org/novavax-reports-fourth-quarter-and-2009-year-end-financial-results-141125/ - Cached•Announced positive pre-clinical data for RSV vaccine candidate. To date, there are no approved vaccines available for RSV.•Received from the National Institution of Health (NIH) a grant for RSV vaccine program, which will support continued pre-clinical development of the RSV vaccine candidate.Read more: http://www.faqs.org/sec-filings/100312/NOVAVAX-INC_8-K/v177139_ex99-1.htm#ixzz0jS5jRK4P

It’s 2010 and Investor Village is still looking for a cure? (That’s gotta tell you something.)

http://www.investorvillage.com/smbd.asp?


THINK TWICE

http://www.thinktwice.com/ploys.htm

In 1963, the recommended age for measles vaccination was 9 months. In 1965 it was changed to 12 months. In 1976 it was changed to 15 months.(230) However, since fewer moms have natural immunity to measles today — due to the large number of mothers who received childhood shots in the 1960s, 1970s, and 1980s — and therefore cannot pass protective antibodies on to their infants, outbreaks of cases are now occurring in children under 15 months of age.(231) In fact, by 1993, more than 25 percent of all measles cases were appearing in babies under one year of age.(232) As a result, in some areas of the country the recommended age to receive the measles vaccine was lowered again, bringing us full circle to initial recommendations — when most children were, according to medical authorities, “inappropriately vaccinated!”(233)

NO SAFE ??? WHAT DO YOU MEAN “NO SAFE” ???

http://www.ncbi.nlm.nih.gov/pubmed/19864390Virol. 2010 Jan;84(2):1148-57. Epub 2009 Oct 28.Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA.College of Veterinary Medicine, Department of Infectious Disease, 111 Carlton Street, University of Georgia, Athens, Georgia 30602, USA.

NOW READ THE FINE PRINT:

Respiratory syncytial virus (RSV) infection causes substantial morbidity and some deaths in the young and elderly worldwide. There is no safe and effective vaccine available, although it is possible to reduce the hospitalization rate for high-risk children by anti-RSV antibody prophylaxis. RSV has been shown to modify the immune response to infection, a feature linked in part to RSV G protein CX3C chemokine mimicry. This study determined if vaccination with G protein polypeptides or peptides spanning the central conserved region of the G protein could induce antibodies that blocked G protein CX3C-CX3CR1 interaction and disease pathogenesis mediated by RSV infection. The results show that mice vaccinated with G protein peptides or polypeptides containing the CX3C motif generate antibodies that inhibit G protein CX3C-CX3CR1 binding and chemotaxis, reduce lung virus titers, and prevent body weight loss and pulmonary inflammation. The results suggest that RSV vaccines that induce antibodies that block G protein CX3C-CX3CR1 interaction may offer a new, safe, and efficacious RSV vaccine strategy. There is no safe and effective vaccine available, although it is possible to reduce the hospitalization rate for high-risk children by anti-RSV antibody prophylaxis.

RECAP: There is no safe and effective vaccine available, although it is possible to reduce the hospitalization rate for high-risk children by anti-RSV antibody prophylaxis. RSV has been shown to modify the immune response to infection, a feature linked in part to RSV G protein CX3C chemokine mimicry.

It has to be alive in order to work best ???

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448562RSV infects nearly all children by age 2 years. The global annual infection and mortality figures for RSV are estimated to be 64 million and 160 000, respectively. The disease spectrum includes a wide array of respiratory symptoms, from rhinitis and otitis media to pneumonia and bronchiolitis, the latter 2 being associated with substantial morbidity. In industrialized countries, RSV is a well-documented cause of yearly winter and spring epidemics of bronchiolitis and pneumonia, which are responsible for 18 000 to 75 000 hospitalizations and 90 to 1900 deaths annually in the United States. Existing data clearly indicate that RSV also accounts for a high proportion (20% to 30%) of LRI cases in children aged 1 to 4 years in developing countries.RSV belongs to the Paramyxoviridae family, genus Pneumovirus. Two subgroups, A and B, have been described, primarily based on differences in the antigenicity of the surface glycoprotein (G). Two factors have complicated the development of vaccines to prevent RSV infection. First, host immune responses appear to play a role in the pathogenesis of disease, as early studies with a Formalin-inactivated vaccine showed that vaccine recipients suffered from more severe disease. Second, naturally acquired immunity is neither complete nor durable and recurrent infections occur frequently. Purified fusion protein vaccines have been shown to be safe and immunogenic in 12- to 48-month-old children. A subunit vaccine containing the RSV F, G, and M proteins, now in phase II in Canada and Australia, has exhibited an excellent safety and immunogenicity profile. Another candidate vaccine is a synthetic peptide of the conserved region of the G protein administered intranasally. Live attenuated RSV vaccines based on temperature-sensitive, cold-adapted strains of the virus that could be delivered to the respiratory mucosa are probably among the most promising approaches.

RECAP: Live attenuated RSV vaccines based on temperature-sensitive, cold-adapted strains of the virus that could be delivered to the respiratory mucosa are probably among the most promising approaches.”


DON'T BE DECEIVED. THE RSV VACCINE IS NOT SAFE. I HAVE A LITTLE BABY GIRL IN THE HOSPITAL RIGHT NOW SUFFERING FROM PARALYSIS DUE TO THE NEURO-TOXINS INTRODUCED TO HER BLOODSTREAM FROM THIS SUPPOSEDLY "SAFE" VACCINATION. Pass it on.